In the BioHarmony Drug Report Database

"Preview" Icon

Insulin degludec

Tresiba (insulin degludec) is a protein pharmaceutical. Insulin degludec was first approved as Tresiba on 2013-01-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus.

 

Trade Name

 

Tresiba
 

Common Name

 

insulin degludec
 

ChEMBL ID

 

CHEMBL2107869
 

Indication

 

diabetes mellitus, hyperglycemia, type 1 diabetes mellitus, type 2 diabetes mellitus
 

Drug Class

 

Image (chem structure or protein)

Insulin degludec structure rendering